Chronic hepatitis C in african americans and other minority groups
Chronic hepatitis C virus (HCV) is the most common Blood borne infection in the United States. An estimated 2.7 million Americans are infected, with the greatest prevalence of infection in African Americans at 3.2%. African Americans account for 22% of Americans with HCV. Recent studies have shown that African Americans are less likely to have cirrhosis than similarly infected non-Hispanic white patients and are more likely to have genotype 1 infection and to develop hepatocellular carcinoma. Several studies have shown that the response rates of African Americans to interferon and ribavirin are significantly lower than those for non-Hispanic whites. Despite the relatively low percentage of African-American patients in these early studies, similar preliminary results are being found in larger prospective studies with the newer treatment regimens of pegylated interferon and ribavirin. Differences in immunologic status, viral kinetics, and iron studies have also been found in HCV-infected African-American patients. Less is known about Mexican Americans and other minority groups because they are poorly represented in clinical trials. Efforts at increasing racial diversity in clinical trials are ongoing.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 2.Hadziyannis SJ, Cheinquer H, Morgan T, et al.: Peginterferon alfa-2a (40 kD) (Pegasys) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind multicentre study examining effect of duration of treatment and RBV dose. J Hepatol 2002, 36(Suppl 1):S3.CrossRefGoogle Scholar
- 4.Fleckenstein JF, Ismail MK, Bockhold K, et al.: African American response rate to therapy for hepatitis C. Hepatology 1998, 28:283A.Google Scholar
- 11.Seef LB: Natural history of chronic hepatitis C. Hepatology 2002, 35 (Suppl):S35-S46.Google Scholar
- 13.National Institutes of Health. http://www.clinicaltrials.gov/.Accessed October 1, 2003.Google Scholar
- 14.Jeffers LJ, Cassidy W, Howell C, et al.: Peginterferon alfa-2a (40KD)(Pegasys) in combination with ribavirin in African American and Caucasian patients with HCV genotype 1: an interim report of a comparative, multicenter, efficacy and safety study. Hepatology 2002, 36:359A.Google Scholar
- 15.Mallat D, Young L, Milikowski C, et al.: The histopathological impact of race in veterans with HCV infection. Hepatology 2000, 32(Suppl 2):A281.Google Scholar
- 18.Muir AJ, Bornstein JD, Killenburg PG, et al.: Pegylated interferon alfa-2b and ribavirin for the treatment of chronic hepatitis C infection in African American and non-Hispanic whites: a preliminary report. Gastroenterology 2002, 122(Suppl 1):A-630.Google Scholar
- 20.DeMaria N, Colantoni A, Idilman R, et al.: Impaired response to high-dose interferon treatment in African-Americans with chronic hepatitis C. Hepatogastroenterology 2002, 49:788–792.Google Scholar